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ABSTRACT 
          Living humans, elicit certain specific biochemical parameters characteristic of their physiological state. Similarly, various 
changes in the chemical composition occur in the body after death. Some of these biochemical parameters can be used as 
biomarkers both for disease diagnosis as well as for gaining a deep understanding of the changes during post-mortem. 
Biomarkers thus help in understanding the physiological state of an individual, the progression of disease, the effectiveness of 
various treatments that are targeted to cure the disease, the prognosis of such diseases as osteoarthritis, post-polio syndrome, 
ovarian cancer, osteosarcoma, alzheimer’s disease etc. Post-mortem degradation products such as amino acids, hypoxanthine, 
volatile organic compounds and various proteins are some biomarkers that are used to understand the phenomenon of post-mortem. 
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INTRODUCTION 
            Biomarkers include tools and technologies that can aide in 
understanding the prediction, cause, diagnosis, progression, 
regression or outcome of treatment of diseases. 
They can be a means for homogenous classification of a disease 
and risk factors and extend our basic information about the 
pathogenesis of disease. They reflect the entire spectrum of 
disease from earliest manifestations to the terminal stages. They 
can be measured in biological fluids like blood, serum, 
cerebrospinal fluid, in tissues or even in a particular cell of 
interest. Biomarkers are rapidly becoming a subject of great 
interest in the fields of observational and analytical epidemiology, 
randomized clinical trials, screening and diagnosis, and prognosis 
of diseases. 
Biomarkers can be defined in various ways:- 
A biomarker or biological marker is any measurable substance in 
the body that can be an indicator or pathological state or a measure 
of response to a therapeutic intervention. (or) Biomarkers are 
cellular, biochemical or molecular alterations that are measurable 
in biological media such as human tissues, cells or fluids. (or) 
Biological characteristics that can be objectively measured and 
evaluated as an indicator of normal biological processes, 
pathogenic processes or pharmacological responses to a 
therapeutic intervention. 
Types of biomarkers: 
Biomarkers can be broadly divided into two groups 
1. Biomarkers of exposure/ antecedent biomarkers:- 
When a disease is suspected resulting from a toxic exposure, 
researchers wish to measure the degree of exposure. External 
exposure is the measured concentration of the toxin in an 
individual’s immediate environment. Direct measurement of the 
alleged toxin in the air, water, soil, or food can provide accurate 
information regarding the “dose” of the exposure. When the toxin 
is identified in tissues or body fluids it becomes a biomarker for 
the internal dose. A biomarker that measures a “biologically 
effective dose” generally indicates the amount of toxin or 
chemical measured in the target organ or its surrogate. Most 
biomarkers of exposure measure antecedent factors thought to 
modify [increase or decrease) the risk of developing the disease 
investigated. The advantage of a biomarker of exposure over a 
history of exposure is that it estimates the actual “internal” dose of 
the exposure. This improves precision in the measurement of any 
risk factor. 
By definition these antecedent biomarkers exist before the disease 
or the outcomes occur and are independent of other exposures. 
They improve the precision in the measurement of other 
associations, because they may be synergistic or antagonistic. 
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Fig 1: Disease pathway and potential impact of biomarkers 
Intermediate Biomarkers- 
 
Some biomarkers represent direct steps in the causal pathway of a 
disease and are therefore strongly related to disease. Others are 
related in some indirect way to the cause. There are numerous 
possibilities to consider. A biomarker could be dependent on 
another known or unknown factor to cause disease. Thus, it is not 
the only determinant but it is in the causal pathway and remains 
strongly related to the disease. 
2. Biomarker of disease:- 
These are used in screening, diagnosis and monitoring of disease 
progression. Biomarkers depict signs that enable earlier diagnosis 
or allow for the outcome of interest to be determined at a more 
early stage of disease. Blood, urine, and cerebrospinal fluid 
provide the necessary biological information for the diagnosis. In 
these conditions, biomarkers are used as an indicator of a 
biological factor that represents either a subclinical manifestation, 
stage of the disorder, or a surrogate manifestation of the disease.  
The potential uses of this class of biomarkers include: 1) 
identification of individuals destined to become affected or who 
are in the “preclinical” stages of the illness, 2) reduction in disease 
heterogeneity in clinical trials or epidemiologic studies, 3) 
reflection of the natural history of disease encompassing the 
phases of induction, latency and detection, and 4) target for a 
clinical trial. [1] 
 
VARIABILITY IN BIOMARKERS: 
Although biomarkers have numerous advantages, variability is a 
concern. Variability applies regardless of whether the biomarker 
represents an exposure or effect modifier, a surrogate of the 
disease, or an indication of susceptibility. Interindividual 
variability can result from the amount of an external exposure or 
from the way a putative toxin is metabolized. For example, 
individuals exposed to the same chemical might differ in their 
ability (or inability) to metabolize the agent, or they may have 
experienced different types of exposures (in the field as compared 
with in the office). Intraindividual variability is usually related to 
laboratory errors or other conditions, or exposures unique to the 
individual. Group variability is also encountered, but this is often 
the desired outcome of a study. [1] 
Biomarkers are of various types: 
1. Anthropomorphic Biomarkers- are of the body shape/form. 
               E.g. Body mass index. 
2. Cellular Biomarkers- are whole cells. 
        E.g. Cancer cells identified by Pap test. 
3. Biochemical Biomarkers- Are substances or products of 
chemical reactions in living organisms.            E.g. Cholesterol 
and bilirubin. 
4. Genomic Biomarkers- Are variants in the DNA sequence or 
in the transcription level. 
               E.g. HER2 or RNA. 
5. Physiological Biomarkers- Are body processes. 
E.g. Systolic Blood Pressure. 
6. Proteomic Biomarkers- are variants in protein sequences, 
protein levels in a given tissue, protein interactions and 
enzyme activities. 
7. Structural Biomarkers- Are anatomical structures. E.g. 
Hippocampus or are lesions  
E.g. Atherosclerosis Plaque. 
 
PROTEIN BIOMARKERS 
Proteins are more diverse and therefore potentially more 
informative and suitable as biomarkers. Protein biomarkers are 
produced as an effect of the disease, exposure to toxic agents, drug 
administration and are good indicators of the physiological state.  
 
The complex composition of protein in blood, post-translational 
modifications, low relative abundance, sequence variations, and 
difficulties associated with the development of high-affinity 
detection agents render the discovery and development of new 
protein-based biomarkers challenging and expensive. 
When choosing a biomarker for study, its reproducibility and 
concentration, high enough to allow for its consistent detection 
and evaluation should be considered. 
Proteins as Disease Biomarkers 
Proteins have extensively been studied as biomarkers in various 
disease conditions, where their study has been useful for 
researchers to gain more information about the disease, its 
progression and development of effective drugs. Protein 
biomarkers have been extensively studied in cancer, osteoarthritis, 
rheumatoid arthritis, renal and kidney failure, osteosarcoma, 
transplantation etc. 
In a study on knee osteoarthritis, [2] using serum and urine 
biomarkers for pain, Ishijima et.al (2011) studied a hypothesis that 
there is a relationship between the onset of early stage 
radiographically defined knee osteoarthritis pain and changes in 
biomarker of joint metabolism. The results suggested that changes 
in cartilage matrix turnover detected by molecular biomarkers 
may reflect changes in cartilage structure that account directly or 
indirectly for knee pain. 
Protein biomarkers for Post-Polio Syndrome [3] has also been 
of interest. 
Survivors of Poliomyelitis often develop increased or new 
symptoms decades after the acute infection, a condition called 
Post- Polio Syndrome (PPS). 
A study undertaken by Gonzalez et.al (2009), intended to find 
protein biomarkers in PPS patients that could be helpful in 
understanding the pathogenesis of the disease and its diagnosis. 
Using cerebrospinal fluid, from normal as well as patients with 
PPS, and applying the techniques of 2 D gel electrophoresis and 
mass spectrometry, the investigators found 5 distinct proteins, 
gelsolin, hemopexin, peptidylglycine alpha amidating 
monooxygenase, glutathione synthetase and kallikrein 6, 
respectively, to be present in the CSF of patients, in comparison 
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with the control groups. An independent ELISA confirmed the 
increase of kallikrein 6, in PPS patients. 
The identification and validation of early detection biomarkers 
highly specific to ovarian cancer, which would permit 
development of minimally invasive screening methods for 
detecting early onset of the disease, are also under study. 
Current practices for early detection of ovarian cancer include 
transvaginal ultrasonography, biomarker analysis, or a 
combination of both. Biomarkers for early detection of ovarian 
cancer include KLK6/7, GSTT1, PRSS8, FOLR1, ALDH1, and 
miRNAs [4]. 
The liver plays a central role in metabolizing xenobiotics; 
therefore, it is highly susceptible to toxicity from these chemicals. 
Certain drugs, when taken in overdose and sometimes even when 
used within therapeutic range, may cause injury to the organ. 
Drug-induced liver injury is now a leading cause of acute liver 
failure. 
Genetic markers used in detecting Drug Induced Liver Injury 
(DILI) 
DILI is strongly affected by genetic predisposition, and by the 
polymorphisms associated with type I and II drug metabolizing 
enzymes. Various genetic polymorphisms in drug metabolizing 
enzymes and immunological mediators such as human leukocyte 
antigen (HLA) molecules and cytokines have been shown to 
correlate well with the patients’ susceptibility to DILI. 
The polymorphisms of these genes may be able to serve as 
markers to predict susceptibility of exposed individuals to DILI. 
Advanced technologies such as genome-wide association studies 
(GWAS) and highly parallelized next-generation sequencing 
(NextGen) are now providing new methods to explore the 
association between genetic predisposition and DILI. For 
example, a GWAS study revealed that the HLA-B*5701 genotype 
is a major risk factor and ST6GAL1 is a possible cofactor of an 
individual’s vulnerability to flucloxacillin-induced DILI. 
Blood biomarkers used in detecting DILI 
 
In addition to genetic markers, histological examination and 
imaging, the most common tests used in the clinic are based on the 
concentration changes of specific molecules in different body 
fluids, especially blood. 
 
Different types of blood DILI biomarkers including metabolites 
(8-hydroxy-2'-deoxyguanosine in urine), proteins (FL-K18 /cK18 
in urine), and DNA (mt/nuclear DNA fragments in plasma) have 
been studied in human [5]. 
In a comparative proteomic study between human osteosarcoma 
cell line (MG-63) and human osteoblastic cell line (normal), using 
iTRAQ- based quantitative differential LC/MS/MS technique, 
342 non-redundant proteins were identified, 68 of which were 
differentially expressed with 1.5-fold difference, with 25 
up-regulated and 43 down-regulated. Among those differential 
proteins, 69% were plasma membrane, which are related to the 
biological processes of binding, cell structure, signal transduction, 
cell adhesion, etc., and interaction with each other. 
Of these, a plasma membrane protein CD151, sowed differential 
expression, and its over- expression was confirmed in 
osteosarcoma cells using immunohistochemistry. The study 
further validates the presence of CD151 plasma membrane protein 
in patients and proposes its use as a biomarker. [7] 
Duchenne Muscular Dystrophy (DMD) is an X- linked 
recessive disorder, which results in chronic inflammation and 
severe skeletal muscle degeneration. A study performed by 
E.Abdel-Salam et.al, evaluated the extent of muscle degeneration 
and regeneration, in the blood of DMD patients. 
Levels of Fas and Fas L, Bax/Bcl-2 and plasma DNA fragments 
were measured as markers of apoptosis/ degeneration; and 
Cytokine tumor necrosis factor alpha (TNF-α) and growth factors 
namely basic fibroblast growth factor (bFGF) and vascular 
endothelial growth factor (VEGF) were measured as biomarkers 
of regeneration. 
The researchers found an increase in plasma DNA fragments, Fas 
and Fas L. Also showed an increase in Bax mRNA concentration 
and a consequent decrease in the concentration of Bcl – 2 protein. 
The regeneration biomarker TNF-α and bFGF show an increased 
concentration in patients, whereas VEGF concentration is 
decreased with respect to that in normal subjects. The study 
concludes that FAS/FASL and Bax/Bcl-2 are involved in muscle 
atrophy and degeneration in DMD patients, while the process of 
regeneration is unable to cope with degeneration. Also suggests 
the use of above mentioned biomarkers as a prognostic tool to 
determine disease severity, instead of the invasive technique of 
muscle biopsy [8]. 
Alzheimer’s is a common form of dementia, affecting individuals 
all over the world and hence is a topic of extensive research. 
Currently diagnosis of this disease is done via clinical assessments 
and confirmed by post mortem brain pathology. Hence the 
ongoing research on Alzheimer’s focuses on finding reliable 
biomarkers that will help in prognosis and diagnosis of the 
disease. So far, biomarkers in cerebrospinal fluid (CSF) like 
Aβ40, Aβ42, total tau and phosphorylated tau are shown to be of 
diagnostic value in developed and early Alzheimer’s disease. 
Biomarkers of AD in plasma are still a matter of study. Plasma 
contains very low levels of tau, which are of no use in diagnosis. 
Recent studies have indicated that while plasma Aβ42 levels alone 
may not be a good biomarker for AD diagnosis; its levels are 
increased in early AD and changes in its level could indicate a 
transition from Mild Cognitive Impairment to Alzheimer’s 
disease[9]. 
Myocardial Infarction is one of the major heart conditions 
leading to mortality in humans. Serum/blood protein biomarkers 
of MI are now being used for risk factor assessment or diagnosis 
of this condition.  
Two well-known protein biomarkers in use for diagnosis of acute 
myocardial infarction are Creatine-Kinase-MB isoform and 
Cardiac Troponin. In 2000, Cardiac Troponin replaced CK-MB as 
the biomarker of choice for diagnosing a myocardial infarction. 
Troponin is a protein released from myocytes when irreversible 
myocardial damage occurs, and its level is dependent on size of 
infarct. Troponin levels peak at 12 hours, and stay elevated for 10 
days or more. Another protein biomarker, Copeptin is the more 
stable surrogate of arginine vasopressin (AVP), with well-known 
effects on osmoregulation and cardiovascular homeostasis. Post 
Acute Myocardial Infarction, vasopressin is thought to (1) 
increase peripheral vasoconstrictor activity thus increasing 
afterload and ventricular stress; (2) increase protein synthesis in 
myocytes leading to hypertrophy and (3) vasoconstriction of 
coronary arteries. Copeptin is released in stoichiometric 
proportion to vasopressin and is stable and easily assayed. 
Another biomarker, Heart-Type Fatty Acid Binding Protein 
(H-FABP) is a low molecular weight protein involved in 
myocardial fatty-acid metabolism. It is also found in small 
quantities in brain, kidney and skeletal tissue and levels can go up 
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in acute ischaemic strokes and intense exercise. It is rapidly 
released early in myocardial infarction and necrosis, into the 
cytosol but not used as a sole biomarker of AMI due to improper 
results in studies [10] 
Advanced glycation end products (AGE’s) is another example 
of biomarkers used in disease prognosis. AGE’s are 
heterogeneous group of macromolecules that are formed by the 
non-enzymatic glycation of proteins, lipids and nucleic acids. 
AGE’s are formed in the human body during the normal aging 
process, but their formation is accelerated during diabetes and 
oxidative stress. A study by Yaffe et.al suggests that higher 
peripheral AGE (pentosidine) concentration is associated with the 
risk of cognitive decline in elder adults. Increased AGE levels are 
also linked to age related conditions including inflammation, 
vascular disease and chronic kidney disease [11]. 
MicroRNAs (miRNAs) are small noncoding RNA molecules that 
can modulate gene expression in a wide range of biological 
process. By binding to the target messenger RNA (mRNA). Seed 
sequence complementarity of ~7 base pairs enables miRNA to 
bind to the target mRNA. The direct interaction of the seed 
sequence with their target mRNAs can result in the inhibition of 
translation or in the reduction in the stability of the mRNA, both of 
which can result in decreased expression of the target protein. 
Most miRNA sequences are conserved across species; the 
expression of some miRNAs is specific to tissues or biological 
stages; and the level of miRNAs can be easily measured by 
quantitative PCR, which allows for high-precision signal 
amplification. Thus, detection of miRNA can be sensitive, 
predictive, specific, robust, translatable, and noninvasive, all 
characteristics of the ideal biomarker. miRNA, like proteins, have 
tissue specific expression patterns. 
MicroRNAs (miRNAs) belong to a class of small non protein 
coding RNA molecules of 18 to 22 nucleotides in length that 
negatively regulate gene expression. Their small size makes them 
less prone to degradation, making them a useful molecular tool for 
forensic body fluid identification. Using microarray technique, all 
5 body fluids, namely blood, semen, menstrual blood, saliva and 
vaginal secretion, could be clearly differentiated from each other, 
based on miRNA expression.  
Time- wise stability of miRNA markers was also determined in 
blood and semen. Samples collected at the start of the study were 
aged for a period of 1 year, under lab conditions. Using 
quantitative RT-PCR technique, miRNA expression profiles 
obtained showed similarity with those obtained at the start; also 
absolute expression levels did not diminish in old samples [17]. 
All the researches considered present a good example for the use 
of biomarkers in prognosis and diagnosis of various diseases. The 
levels of various disease biomarkers when monitored accurately 
will aide in proper diagnosis and use of proper treatments.    
 
BIOMARKERS: AFTER LIFE 
Biomarkers are not only of great value when studied with respect 
to disease prognosis or diagnosis in living human beings, but also 
are of great value in post mortem analysis. Biomarkers can 
provide a great deal of information regarding the process of post 
mortem changes taking place in the human body, under various 
conditions.  
The human body starts to decay in about 4 minutes after death. 
The decomposition process is affected by many factors: method 
and time of burial, corpse-specific characteristics (weight, sex, 
age, cause of death) and conditions of the resting place 
(temperature, pH, insect and carnivore activity, moisture, and soil 
type). Microbiology plays a major role in decomposition: 
protozoa, fungi, aerobic and anaerobic bacteria are involved. 
The onset of decay is governed by a process called autolysis – or 
self-digestion. As cells of the body are deprived of oxygen, carbon 
dioxide in the blood increases, pH decreases and wastes 
accumulate which poison the cells. Concomitantly, unchecked 
cellular enzymes (lipases, proteases, amylases, etc.) begin to 
dissolve the cells from the inside out, eventually causing them to 
rupture, and releasing nutrient-rich fluids. 
Autolysis usually does not become visually apparent for a few 
days. It is first observed by the appearance of fluid filled blisters 
on the skin and skin slippage where large sheets of skin slough off 
the body. Meanwhile, the body has acclimated to ambient 
temperature (algor mortis), blood has settled in the body causing 
discoloration of the skin (livor mortis) and cellular cytoplasm has 
gelled due to increased acidity (rigor mortis). After enough cells 
have ruptured, nutrient-rich fluids become available and the 
process of putrefaction begins. 
Putrefaction is the destruction of the soft tissues of the body by the 
action of micro-organisms (bacteria, fungi and protozoa) and 
results in the catabolism of tissue into gases, liquids and simple 
molecules. Usually, the first visible sign of putrefaction is a 
greenish discoloration of the skin due to the formation of 
sulfhaemoglobin in settled blood. The process progresses into 
distension of tissues due to the formation of various gases. 
Saponification (the formation of soap from fat under high pH 
conditions) or adipocere formation typically occurs after the onset 
of putrefaction in warm, moist, environments and is seen as 
deposits of a yellowish-white, greasy, wax-like substance. 
Adipocere develops as the result of fat hydrolysis with the release 
of fatty acids. Mummification is typically the end result of tissue, 
usually skin, with no nutritional value, which has survived the 
active decay process and is formed by the dehydration or 
desiccation of the tissue. Remaining skin is converted into a 
leathery or parchment-like sheet which clings to bone. 
Mummification most commonly develops in conditions of dry 
heat or in areas that have very low humidity, such as in arctic 
regions or deserts.  
Bone goes through yet another complex process called diagenesis. 
Diagenesis is a natural process that serves to alter the proportions 
of organic (collagen) and inorganic components (hydroxyapatite, 
calcium, magnesium) of bone exposed to environmental 
conditions, especially moisture. [12]. The study of post mortem 
decomposition is of great use in forensic investigations, where the 
stage of decomposition helps in determining the time of death. 
Various biomarkers have been studied or developed that are of 
great use in forensic investigations. 
The study of mammalian soft tissue decomposition is an emerging 
area in forensic science, with a major focus being the use of 
various chemical and biological methods to study the fate of 
human remains in the environment. 
Decomposition of mammalian soft tissue, depends on 
environmental conditions and physiological factors and will 
proceed until complete disintegration of the tissue occurs. An 
understanding of this process is extremely important for 
investigations of suspicious deaths as it complicates determination 
of cause of death and makes the estimation of postmortem interval 
very difficult. The major stages of decomposition involve 
complex reactions which result in the chemical breakdown of the 
body’s main constituents; lipids, proteins, and carbohydrates. As 
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decomposition proceeds, these macromolecules degrade to their 
structural components which include amino acids, fatty acids, and 
glucose. Soft tissue decomposition can be studied using 
chromatographic as well as non-chromatographic techniques. 
The process of soft tissue decomposition results in a release of 
nutrients into the soil surrounding a cadaver. A proportion of these 
nutrients result from the release of nitrogen-containing 
compounds within the body, which include proteins, peptides, 
amino acids, and amines. These nitrogenous compounds have the 
ability to react with ninhydrin. It has been hypothesized that the 
decomposition of a body would result in an increase in ninhydrin 
reactive nitrogen (NRN) and may provide a new technique for 
identifying grave soil (i.e. soil associated with a decomposing 
cadaver).  
Adipocere, a postmortem decomposition product may be found 
directly on decomposed remains or in the surrounding soil 
environment, especially in burials. Spectroscopic techniques have 
also been applied to forensic decomposition studies to identify 
fatty acid concentrations indicative of adipocere formation. The 
use of infrared spectroscopy as a qualitative tool for determining 
the lipid profile of soft tissue has been well documented. 
In the early stages of postmortem interval, one of the most widely 
reported biochemical method to estimate postmortem interval is 
the determination of potassium ion (K+) and hypoxanthine (Hx) 
concentrations in vitreous humor.  
The vitreous humor refers to the fluid that fills the vitreous body 
(or posterior chamber) of the eye. Its potential usefulness for 
postmortem chemical analysis results from it being anatomically 
confined and thus somewhat ‘protected’ and preserved for longer 
time periods from bacterial contamination, enzymatic activity and 
putrefactive changes. It has also been stated that vitreous humor 
has advantages for chemical analysis for biomarkers compared to 
the use of blood and cerebrospinal fluid (CSF) due to accessibility, 
ease of sampling, less susceptibility than blood to rapid chemical 
changes and relative independence from environmental 
influences. 
Hypoxanthine (Hx) is a degradation product of adenosine and is 
elevated due to hypoxia prior to death. Hypoxanthine has 
previously been analysed by high performance liquid 
chromatography (HPLC) with applications generally in the 
pharmaceutical and medical fields. The potential for the use of 
vitreous Hx as a postmortem interval indicator was first described 
by Rognum et al (1991). Vitreous humor has also been analysed 
for free amino acids.  
Small organic molecules, such as short chain volatile fatty acids 
(C2–C5), were the primary focus of early studies into the 
chemistry of decomposition in the mid-late postmortem interval. 
The analysis of VFAs has typically been carried out using gas 
chromatography (GC). 
Volatile organic compounds (VOCs) associated with 
decomposition have long been used as a means of training cadaver 
dogs to aid in the detection of clandestine graves.  VOCs evolved 
from a decaying body were analysed by TD/GC–MS to provide a 
chemical profile of decomposition. 
Though not directly related to the estimation of postmortem 
interval, one of the most widely studied decomposition products is 
adipocere. While FTIR analysis has been useful in studying 
trends, analysis of adipocere using GC–MS has allowed a more 
detailed understanding of its composition. [13] 
The determination of the date of death from bone remains is of 
scientific interest but also has important legal implications. The 
establishment of the postmortem interval (PMI) is a very complex 
problem because of the great number of intrinsic factors that may 
alter the normal course of postmortem change, such as the age, 
sex, constitution and previous physiological and pathological 
states of the subject, and external factors. 
The mineral phase of bone is constituted of poorly crystalline 
hydroxylapatite, characterized by the presence of numerous 
foreign ions. Biological apatites can exhibit different chemical 
compositions, crystallinity and stability depending on several 
factors. Among these factors, crystal size has an important role 
because it determines the surface area and, as a consequence, 
influences the stoichiometry and the solubility properties of 
biological apatites. 
As bone decays, the organic matter undergoes disintegration, 
which leads to the formation of simple chemical substances. In 
this respect, the variation in the proteins and amino acids found in 
bones has been studied by several authors. Modifications of the 
bone lipids have also been studied. Of special importance are 
techniques used to study the mineral components of bone since 
these, too, vary with time. Variations in nitrogen concentration 
and other components such as iron, lead, zinc, phosphorus, 
magnesium and potassium contents have also been studied. 
Strontium and barium in human bones are commonly used as 
indicators for varying diets in paleodietary studies. 
Castello.M.J (2007), et.al, studied potassium, sulphur, nitrogen, 
urea, total protein, phosphorus, and some X-ray diffraction (XRD) 
parameters related to the degree of crystallinity of the mineral 
component in medullar and cortical bone zones to establish which 
of the two provide the most useful information for calculating the 
PMI. The study inferred a high concentration of nitrogen and urea 
in the medullar bone and a high sulphur, potassium, and protein 
value in cortical zone. Researchers propose the use of both XRD 
and biochemical analyses (especially of urea, potassium and 
sulphur) particularly in the cortical zone of the bone to be an 
alternative method for dating osseous remains. [14] 
For almost half a century it has been recognized that there are 
pronounced biochemical changes post-mortem, especially in the 
brain. Post-mortem interval affects the proteome, in some cases 
within minutes of death. 
A study was designed to assess the influence of high energy 
head-focused microwave irradiation and the postmortem interval 
on measurements of the mouse brain proteome. 
Difference gel electrophoresis was used to compare mouse brain 
protein levels in animals killed by decapitation, where the tissue 
was held at 25°C for selected time intervals post-mortem, and by 
high-energy head-focused microwave irradiation followed by 
immediate resection. Microwave-mediated killing was used 
because it comprehensively snap-inactivates enzymes while 
largely retaining brain cytoarchitecture. The aim of this study was 
to establish the influence of two key factors on the brain proteome: 
(i) the method of death and (ii) the post-mortem interval. Using 
two dimensional difference gel electrophoresis for protein 
separation and MALDI-TOF MS identification of proteins, 
researchers inferred the use of high-energy head-focused 
microwave killing, when compared with decapitation, minimizes 
the potential for post-mortem changes in brain protein levels, 
including post-translational modifications. 
Findings of the study indicate that the large majority of brain 
proteins are stable during a post-mortem interval of up to 4 h at 
25°C. However, several proteins thought to be of critical 
importance to synaptic and/or neurological function were found to 
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change rapidly after death, and many of these were 
phosphoproteins. [15] 
A study by Tavichakorntrakool et.al (2008), performed a serial 
analysis of post mortem changes in proteome profile, histology, 
electrolytes (K, Mg and Ca) contents, water composition and LDH 
enzyme activity in vastus lateralis muscle. 
The study aimed to obtain preliminary data that could be used as 
guidance for the determination of the longest postmortem interval 
for reliable proteomic, histological, chemical and biochemical 
studies. 
Using the above mentioned set of markers, researchers were able 
to demonstrate that storing the muscle samples at 4°C could delay 
some of the post mortem changes, which occur more rapidly at 
25°C. [16] 
 
CONCLUSION:  
Biomarkers are important biochemical parameters that are used to 
study various aspects of diseases and also used to study the 
postmortem changes that take place in human body after death.  
Biomarkers are now an integral part of disease diagnosis and 
treatment of diseases. New biomarkers when discovered should be 
properly validated taking into consideration the various aspects of 
age, gender, stage of disease etc that may be a cause of variation.  
Better techniques for discovery and validation of various 
biomarkers should be developed so that biomarkers with desired 
characteristics can be developed and used to study the desired 
characteristic.   
 
REFERENCE: 
1. Richard Mayeux, Biomarkers- Potential uses and limitations. 
NeuoRx: The Journal of the American Society for 
experimental Neurotherapeutics, vol.1, (2004), 182-188. 
2. Ishijima et.al, Relationships between biomarkers of cartilage, 
bone, synovial metabolism and knee pain provide insights 
into the origins of pain in early knee osteoarthiritis, Arthiritis 
Research and Therapy, 13. (2011). 
3. Gonzalez et.al; Identification of novel candidate protein 
biomarkers for the post-polio syndrome – implications for 
diagnosis, neurodegeneration and neuroinflammation, J.Prot 
[2009]. 
4. Sreeja et.al; Early detection biomarkers for ovarian cancer, 
Journal of oncology, vol. 2012. 
5. Zhou Y, Qin S, Wang K; Biomarkers of drug-induced liver 
injury, Current Biomarker Findings, 3 (2013) 1-9. 
6. Hewitt S, Dear J, Star R.A; Discovery of protein biomarkers 
for renal diseases, J.Am. Soc Nephrol, 15 (2004)1677-1689. 
7. Zhang et.al; Comparative proteomic analysis of plasma 
membrane proteins between human osteosarcoma and normal 
osteoblastic cell lines. BMC Cancer (2010), 10: 206. 
8. C. Abdel-Salam, I. Abdel-Meguid, Korra S S; markers of 
deneration and regeneration in Duchenne Muscular 
Dystrophy, Acta Myologica, XXVIII, (2009) 94-100. 
9. Chintamaneni M, Bhaskar M; Biomarkers in Alzheimer’s 
Disease: A review, ISRN Pharmacology, vol 2012. 
10. Cheng D and Ng LL; Biomarkers in acute myocardial 
infarction, BMC Medicine, (2010), 8:34. 
11. Yaffe et.al; Advanced glycation end product level, diabetes 
and accelerated cognitive aging. Neurology, 77 (2011) 
1351-1356. 
12. Vass A A; beyond the grave- understanding human 
decomposition. Microbiology today, vol 28, Nov 2001. 
13. Swaan L.M, Forbes S.L, Lewis S.W; Analytical separations 
of mammalian decomposition products for forensic science: 
A review. Analytica Chemica Acta, 682 (2010) 9-22. 
14. Castello-Prieto et.al; Application of biochemical and X ary 
diffraction analysis to establish the post mortem interval. 
Forensic Science International 172 (2007), 112-118. 
15. Hunsucker et.al; Assessment of post mortem-induced 
changes to the mouse brain proteome, Journal of 
neurochemistry, 105 (2008) 725-737. 
16. Tavichakorntrakool et.al; Serial analysis of post mortem 
changes in human skeletal muscle: A case study of alterations 
in proteome profile, histology, electrolyte contents, water 
composition and enzyme activity. Proteomics Clin. Appl. 2 
(2008) 1255-1264. 
17. Zubakaov et.al; MicroRNA biomarkers for forensic body 
fluid identification obtained from microarray screening and 
quantitative RT-PCR confirmation. Int. J. Legal Med 124 
(2010) 127-226. 
  
 
 
Citation: Archana Moon , et al (2014). Protein Biomarkers: In Life and After Life. J. of Advancement in Medical and Life Sciences. V1I3. DOI: 10.15297/JALS.V1I3.01 
 
Copyright: © 2014 Archana Moon. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted 
use, distribution, and reproduction in any medium, provided the original author and source are credited. 
